Takeda Pharmaceutical Company Limited
TKPHF
Other OTC36.78
USD
+0.03
- -
CIK
0001395064
ISIN
JP3463000004
Return %
Stock
S&P500
1Y
26.81
15.01
3Y
18.94
82.56
5Y
11.00
79.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Julie So-Young Kim
- Full Time Employees
- 47,029
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1-1, Nihonbashi-Honcho 2-chome Tokyo OS Japan 103-8668
- IPO Date
- Jun 25, 2008
- CIK
- 0001395064
- Website
- takeda.com
- Similar Companies
- Business
- Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Osaka, Japan, founded in 1781. It specializes in the research, development, manufacturing, and marketing of pharmaceutical products primarily in the therapeutic areas of gastroenterology, oncology, rare diseases, neuroscience, plasma-derived therapies, and vaccines. Its core products include Entyvio (vedolizumab) for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; Takhzyro (lanadelumab) targeting rare genetic conditions; Takecab/Vocinti, a proton pump inhibitor for acid-related disorders; and oncology agents like Adcetris (brentuximab vedotin) and Ninlaro. The company operates in approximately 80 countries worldwide, serving hospitals, healthcare providers, and specialty markets. Recent major changes include a strategic global partnership established in 2025 with Innovent Biologics to license and develop next-generation cancer therapies, expanding Takeda's oncology pipeline significantly outside Greater China, with upfront payments and equity investment totaling over $1.3 billion. Takeda also focuses on regulatory filings and Phase 3 clinical trial results expected during 2025 for new drugs such as rusfertide, oveporexton, and zasocitinib, aiming to accelerate future growth. Additionally, Takeda has completed significant share repurchases and continues rationalizing its portfolio by divesting non-core assets, exemplified by its prior sale of the TachoSil manufacturing operations in Austria and over-the-counter product portfolios, as part of its strategy to concentrate on high-impact pharmaceuticals and specialty therapies. The company maintains a robust R&D-driven approach with a pipeline committed to innovative treatments and sustained long-term value creation. It targets patients with limited or no treatment options and seeks global reach through ongoing external collaborations and internal clinical advancements. Takeda’s diversified therapeutic focus, geographic footprint, and recent strategic expansions position it as a leading player within the global pharmaceutical industry.